FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Lymphokine > Interleukin

Interleukin

Interleukin patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

08/21/14 - 20140234251 - Purine nucleoside analogues for treating flaviviridae including hepatitis c
This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a...

08/21/14 - 20140234252 - Composition and methods for the treatment of degenerative retinal conditions
The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation....

08/14/14 - 20140227221 - Methods of treating multiple myeloma and resistant cancers
Erastin analogs are useful in treating various cancers, particularly multiple myeloma. Erastin analogs are also useful in treating cancers that are resistant to other anticancer agents....

08/14/14 - 20140227222 - Cyclin dependent kinase inhibitors and methods of use
The presently disclosed subject matter relates to methods and compositions for protecting healthy cells from damage due to DNA damaging agents. In particular, the presently disclosed subject matter relates to the protective action of selective cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to or...

08/14/14 - 20140227223 - Pegylated interleukin-10
Interleukin-10 (IL-10) conjugated via a linker to one or more polyethylene glycol (PEG) molecules at a single amino acid residue of the IL-10, and a method for preparing the same, are provided. The method produces a stable mono-pegylated IL-10, which retains IL-10 activity, where pegylation is selective for the N-terminus...

08/07/14 - 20140219955 - Fusion molecules and il-15 variants
The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention....

08/07/14 - 20140219956 - Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (P2PDox) with antibodies or antigen-binding fragments thereof (ADCs), with targetable construct peptides or with other targeting molecules that are capable of delivering the P2PDox to a targeted cell, tissue or pathogen. Once delivered to the target cell,...

07/31/14 - 20140212378 - Method to detect the onset and to monitor the recurrence of chronic graft versus host disease in transplantation patients
The described invention comprises a method for detecting the onset or monitoring the recurrence of chronic graft versus host disease (cGVHD) in a transplantation patient. The method comprises isolating peripheral blood mononuclear cells (PBMCs) from the transplantation patient and analyzing the isolated PBMCs to detect a biomarker specific for a...

07/31/14 - 20140212379 - Il-1 binding proteins
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions....

07/31/14 - 20140212380 - Targets and agents for the treatment of impaired bone fracture healing
The application teaches a composition comprising one or more pharmaceutical active ingredients selected from the group consisting of interleukin-8 (IL-8 or CXCL8), a functional fragment of IL-8, a functional variant of IL-8, and an agonist of IL-8 receptor, for therapeutic and/orprophylactic interventions in impaired bone fracture healing, such as but...

07/24/14 - 20140205560 - Multimeric il-15 soluble fusion molecules and methods of making and using same
The invention provides soluble fusion protein complexes having at least two soluble fusion proteins. The first fusion protein is a biologically active polypeptide covalently linked to an interleukin-15 (IL-15) polypeptide or a functional fragment thereof. The second fusion protein is a second biologically active polypeptide covalently linked to a soluble...

07/24/14 - 20140205561 - Mitigation of cutaneous injury with il-12
The present application relates to treatment of cutaneous wounds using IL-12. The methods of the invention result in improved wound closure. The methods comprise treating cutaneous wounds using topical, subcutaneous, and/or intramuscular administration of IL-12....

07/24/14 - 20140205562 - Il-1 binding proteins
Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions....

07/24/14 - 20140205563 - Compositions derived from stem cell released molecules & methods for formulation thereof
Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (SRM's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and SRM's can be derived from one or more distinct cell lines. The SRM's...

07/24/14 - 20140205564 - Hepatitis c virus inhibitors
The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection....

07/24/14 - 20140205565 - Compositions and methods for treating organ dysfunction
A method of retarding cellular senescence comprising (i) providing an extracellular matrix (ECM) composition comprising ECM from an adolescent tissue source, the ECM comprising an exogenously added cytokine, and (ii) administering ECM composition to an organ with cells exhibiting cellular senescence, wherein, the cytokine interacts with at least one molecule...

07/17/14 - 20140199259 - Stabilized liquid formulation
The present invention relates to a liquid formulation comprising an active substance and protamine, wherein the liquid formulation differs from a suspension....

07/17/14 - 20140199260 - Compositions and methods for the treatment of hiv
Compositions and methods for the treatment of HIV are provided....

07/10/14 - 20140193358 - Treating cancer stem cells using targeted cargo proteins
The disclosure provides targeted cargo proteins that are useful for targeting cancer stem cells, and methods of their use in treating cancer....

07/10/14 - 20140193359 - Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate...

07/10/14 - 20140193360 - Hydrogel comprising catechol group-coupled chitosan or polyamine and poloxamer comprising thiol group coupled to end thereof, preparation method thereof, and hemostat using same
The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus...

07/10/14 - 20140193361 - Systemic glucose tolerance in type-2 diabetes
Obesity is associated with a state of chronic low-grade inflammation and the present invention establishes that adipose-resident natural killer T (NKT) cells attenuate inflammation in adipose tissue and improves systemic glucose homeostasis in mice at different stages of obesity. Accordingly, the present invention provides methods of treating type-2 diabetes or...

07/03/14 - 20140186293 - Immunoglobulin-bound extracellular vesicles and uses thereof
Provided are methods of isolating IgG-bound (e.g., IgG-bound or protein G-recognized IgG-bound) extracellular vesicles from a sample containing a biological fluid from a subject, where the IgG (e.g., IgG2 or protein G-recognized IgG) is bound to an antigen present on the surface of the extracellular vesicle and the IgG (e.g.,...

07/03/14 - 20140186294 - Phagocytic activity as a marker of synucleinopathic disease
The invention provides methods of screening for agents useful in treating or prophylaxis of synucleinopathic disease, methods of diagnosis or prognosis of the same and methods of treatment and prophylaxis. The invention is based in part on the result that cells with phagocytic activity from subjects with synucleinopathic disease have...

07/03/14 - 20140186295 - Methods and compositions for the treatment of cancer
Described herein are methods for the treatment of cancer (e.g. melanoma, lung cancer, or other cancers). The methods involve administrating to a subject in need thereof an agonist of the IL-9 receptor (e.g. IL-9), e.g. an agent that binds and activates the IL-9 receptor, or an agent that increases IL-9...

07/03/14 - 20140186296 - Methods for treatment of hiv and other infections using a t-cell or viral activator and anti-retroviral combination therapy
Disclosed is a method for treating infection with a pathogen. The method involves administration of (1) a substance which induces active pathogen replication in a cell latently infected with HIV and (2) an anti-pathogen drug. Also disclosed are methods for expanding CD+ T cells from peripheral blood mononuclear cells isolated...

07/03/14 - 20140186297 - Cd4+ t-cells with cytolytic properties
The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them....

07/03/14 - 20140186298 - T-cell vaccination with viral vectors via mechanical epidermal disruption
Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parastic or tumor antigen to an epidermal tissue such as the skin, lungs or gastrointestinal tract, which has been mechanically disrupted, in an amount effective to elicit or stimulate a cell mediated immune response. The...

07/03/14 - 20140186299 - Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV....

06/26/14 - - Ph20 polypeptide variants, formulations and uses thereof
Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof....

06/26/14 - 20140178331 - Method of treating cerebral hemorrhage and subarachnoid hemorrhage comprising administering metal chelators to the upper one-third of the nasal cavity
Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of cerebral hemorrhage and subarachnoid hemorrhage. Therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially...

06/26/14 - 20140178332 - Il-12/p40 binding proteins
The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro...

06/26/14 - 20140178333 - Homogenous preparations of il-28 and il-29
Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity...

06/26/14 - 20140178334 - Methods and compositions for liquidation of tumors
This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to...

06/26/14 - 20140178335 - Use of il-12 to generate endogenous erythropoietin
The present invention relates to the use of exogenous interleukin-12 (IL-12) for increasing endogenous production of erythropoietin....

06/19/14 - 20140170108 - Compositions useful for the treatment of inflammatory disease or disorders
The present invention provides sustained release and long acting forms of peptide therapeutic, particularly Interleukin-1 receptor antagonist (IL-1ra), including multimeric forms of IL-1ra, including variants of IL-1ra which are capable of multimerising, and compositions comprising the long acting and multimeric forms of IL-1ra, and a process of preparation thereof. The...

06/19/14 - 20140170109 - Il-12 immunoconjugate
Conjugate comprising interleukin-12 (IL-12) and a single chain targeting portion comprising two antigen binding sites. The targeting portion may comprise an antibody fragment such as a single chain diabody. The conjugate may be a single chain fusion protein. Use of single chain bivalent IL-12 immunocytokine for targeting the extra-cellular matrix...

06/12/14 - 20140161766 - Tetrameric cytokines with improved biological activity
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers...

06/12/14 - 20140161767 - Follicle-stimulating hormone (fsh)/lytic domain fusion constructs and methods of making and using same
The invention relates to fusion constructs, methods of using fusion constructs and methods of treating undesirable or aberrant cell proliferation or hyperproliferative disorders, such as tumors, cancers, neoplasia and malignancies....

06/12/14 - 20140161768 - Porcine reproductive and respiratory syndrome virus compositions and uses thereof
Provided herein are embodiments relating to porcine reproductive and respiratory syndrome (PRRS) virus, compositions comprising the virus, and methods of using the virus. The virus may be used to immunize a mammal, including swine. Methods for generating an immune response against PRRS virus in swine by administering a composition comprising...

06/05/14 - 20140154206 - Immunity induction agent
Provided is a novel immunity-inducing agent useful as a therapeutic and/or prophylactic agent for cancer. The immunity-inducing agent comprises as an effective ingredient(s) at least one polypeptide having immunity-inducing activity selected from the polypeptides (a), (b) and (c) below, and/or a recombinant vector(s) that comprise(s) a polynucleotide(s) encoding the at...

06/05/14 - 20140154207 - Kit containing stem cells and cytokines for use in attenuating immune responses
The present invention relates to a composition and methods of treatment for inflammation comprising of adult stem cells and inflammatory cytokines. The invention further relates to the treatment of inflammation associated with autoimmune disorders, allergies, sepsis, cancer as well as to preventing, reducing or treating transplant rejection and/or graft-versus-host disease...

05/29/14 - 20140147411 - Methods of treating cancer and testing mutation zygosity related thereto
In certain embodiments, the disclosure relates to methods of treating cancer comprising administering an effective amount a tyrosine kinase inhibitor in combination with an immunotherapy to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating cancer comprising: i) analyzing both chromosomes in a cell...

05/29/14 - 20140147412 - Spiro compounds as hepatitis c virus inhibitors
Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method...

05/22/14 - 20140140949 - Treatment of obesity
The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via...

05/22/14 - 20140140950 - Business methods, processes and systems for collection, cryogenic storage and distribution of cosmetic formulations from an obtained stem cell based biological material
Business methods, processes and systems for collection, storage and distribution of a biological sample material for producing a cosmetic formulation product....

05/22/14 - 20140140951 - D-alanine ester of rp-nucleoside analog
or a pharmaceutically acceptable salt or solvate thereof....

05/22/14 - 20140140952 - D-alanine ester of sp-nucleoside analog
or a pharmaceutically acceptable salt or solvate thereof....

05/22/14 - 20140140953 - Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
The pharmaceutically acceptable salts of bicycle-substituted pyrazolon azo derivatives represented by the general formula (I), their preparation methods, pharmaceutical compositions containing the same and their use as a therapeutic agent, especially as thrombopoietin (TPO) mimetics and their use as agonists of thrombopoietin receptor. The definitions of substituents in the general...

05/22/14 - 20140140954 - Methods of modulating cytokine activity; related reagents
Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor....

05/15/14 - 20140134128 - Multimeric il-15 soluble fusion molecules and methods of making and using same
The present invention features compositions and methods featuring ALT-803, a complex of an interleukin-15 (IL-15) superagonist mutant and a dimeric IL-15 receptor α/Fc fusion protein useful for enhancing an immune response against a neoplasia (e.g., multiple myeloma, melanoma, lymphoma) or a viral infection (e.g., human immunodeficiency virus)....

05/15/14 - 20140134129 - Rna vaccines
A RNA vaccine containing a RNA molecule encoding an allergen or derivative thereof, in which the allergen is an allergen of Alnus glutinosa, Alternaria alternata, Ambrosia artemisiifolia, Apium graveolens, Arachis hypogaea, Betula verrucosa, Carpinus betulus, Castanea sativa, Cladosporium herbarum, Corylus avellana, Cryptomeria japonica, Cyprinus carpio, Daucus carota, Dermatophagoides pteronyssinus, Fagus...

05/15/14 - 20140134130 - Fused bicyclic oxalamide compounds for the treatment of hepatitis c
Compounds of Formula I, including pharmaceutically acceptable salts thereof, as well as compositions containing these compounds, have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:...

05/15/14 - 20140134131 - Immune regulation
A method of regulating the immune system of a subject that involves removing antigen presenting cells from subject and loading preselected class II peptide fragments onto the subjects APC's outside the body of the subject....